Allergan’s $30 Million Antitrust Settlement Gets Nod From Judge

AbbVie Inc. unit Allergan Inc. is free of antitrust claims brought by a group of pension funds over its alleged scheme to delay generic versions of the dry-eye drug Restasis, after a federal judge in Brooklyn approved their $30 million settlement with the drugmaker.

Judge Nina Gershon signed off Tuesday on the deal resolving class action claims on behalf of pharmaceutical end payers like union and municipal health plans. She previously approved a $51 million settlement between Allergan and the drug distributors pursuing claims on behalf of Restasis bulk buyers.

Gershon also handed $10 million in legal fees and $4.6 ...